Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EPS (Weighted Average and Diluted) (2021 - 2025)

Historic EPS (Weighted Average and Diluted) for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$0.32.

  • Prime Medicine's EPS (Weighted Average and Diluted) rose 2727.27% to -$0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 3009.71%. This contributed to the annual value of -$1.65 for FY2024, which is 2423.79% up from last year.
  • As of Q3 2025, Prime Medicine's EPS (Weighted Average and Diluted) stood at -$0.32, which was up 2727.27% from -$0.41 recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's EPS (Weighted Average and Diluted) registered a high of $0.72 during Q4 2022, and its lowest value of -$4.45 during Q4 2021.
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$0.89, with a median of -$0.46 in 2024.
  • In the last 5 years, Prime Medicine's EPS (Weighted Average and Diluted) skyrocketed by 11617.98% in 2022 and then tumbled by 20000.0% in 2023.
  • Quarter analysis of 5 years shows Prime Medicine's EPS (Weighted Average and Diluted) stood at -$4.45 in 2021, then soared by 116.18% to $0.72 in 2022, then tumbled by 200.0% to -$0.72 in 2023, then skyrocketed by 50.49% to -$0.36 in 2024, then rose by 10.23% to -$0.32 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.32 in Q3 2025, compared to -$0.41 in Q2 2025 and -$0.4 in Q1 2025.